{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-21-133381","form_type":"8-K","ticker":"TVRD","cik":"0001346830","company_name":"Tvardi Therapeutics, Inc.","filed_at":"2021-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.204590+00:00","generated_at":"2026-06-28T13:48:01.896492+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cara Therapeutics appoints Christopher Posner as President and CEO; Derek Chalmers transitions to Senior Advisor","bullets":["Christopher Posner, former LEO Pharma US CEO and current Cara board member, becomes President and CEO effective Nov 9.","Derek Chalmers steps down as President, CEO, and director effective Nov 8; will serve as Senior Advisor through June 2022.","Posner receives $680K base salary, $400K signing bonus, equity awards (566K option shares, 142K RSUs).","Chalmers receives 12 months base salary, COBRA coverage, 2021 target bonus, and extended equity vesting.","KORSUVA injection (FDA-approved for pruritus in dialysis) to launch; oral KORSUVA for atopic dermatitis advanced."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-21-133381","json":"https://secwatch.observer/filing/0001104659-21-133381.json","markdown":"https://secwatch.observer/filing/0001104659-21-133381.md","text":"https://secwatch.observer/filing/0001104659-21-133381.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1346830/000110465921133381/0001104659-21-133381-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1346830/000110465921133381/tm2131541d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T13:48:01.896492+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8a92821c67","claim":"Christopher Posner was appointed as President and CEO at Tvardi Therapeutics, Inc..","evidence_excerpt":"the appointment of Christopher Posner, age 52, a current non-employee director of the Company, to serve as President and CEO of the Company, effective November 9, 2021.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1346830/000110465921133381/0001104659-21-133381-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and CEO"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}